147

therapeutic
published patents

56

oncology
published patents

310

research tools

46

diagnostic
published patents

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

Applications
Therapy areas
More posts

Use of shp2 inhibitors for the treatment of insulin resistance

Despite reaching an epidemic status worldwide, metabolic disorders, notably diabetes, still miss efficient and specific therapeutic strategies because […]

Use of mast cell stabilizer for the treatment of heart failure with

Heart failure with preserved ejection fraction (HFpEF) which results from diastolic dysfunction is a growing epidemiologic problem. However, the […]

Use of triethylenetetramine (teta) for the therapeutic induction of

Autophagy is a universal anti-aging mechanism the chronic induction of which can extend the health span and lifespan of mammals. Here the inventors […]

Gaba administration induces alpha cell-mediated beta-like cell

GABA is an inducer of α-to-β-like cell conversion in vivo. This conversion induces α cell replacement mechanisms through the mobilization of […]

Methods and compositions for promoting wound healing in a subject

The present invention relates to a method for promoting wound healing in a subject suffering from Ectodermal dysplasia in need thereof comprising a […]

Use of ngal inhibitors for treating chronic wound

Chronic wounds and in particular diabetic ulcers are a serious complication of diabetes. Unresolved inflammation, associated with the dysregulation of […]

Inhibitors of ngal protein

This invention relates to compounds that are inhibitors of NGAL activity, and applications thereof. […]

Selective pharmacological inhibition of epac1 for the treatment of

The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IPF. The inventors showed that EPAC1 […]

Nlrp6 supports diurnal oscillation of host-microbiota interactions

The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of […]

Ptgdrs, cxcr4 and basophils in systemic lupus erythematosus

The present invention relates to PTGDRs, CXCR4 and Basophils to treat in Systemic Lupus Erythematosus. In particular, the present invention concerns a […]

More posts

You might also be interested in